There is currently no universally accepted scoring system for FRα IHC in routine diagnostic practice, though clinical trials have converged on a simplified binary scheme based on the percentage of viable tumor cells showing ≥2+ membranous staining [8,9,10,11,12,13,14,15,16]. The gene discussed is FOLR1; the disease is neoplasm.